Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Firefly Neuroscience Inc (AIFF)

Firefly Neuroscience Inc (AIFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,803
  • Shares Outstanding, K 13,493
  • Annual Sales, $ 110 K
  • Annual Income, $ -10,460 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.88
  • Price/Sales 217.39
  • Price/Cash Flow N/A
  • Price/Book 2.42

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4500 +14.48%
on 11/17/25
1.8107 -8.32%
on 11/12/25
+0.0100 (+0.61%)
since 11/11/25
3-Month
1.4500 +14.48%
on 11/17/25
3.1100 -46.62%
on 10/03/25
-1.1100 (-40.07%)
since 09/11/25
52-Week
1.4500 +14.48%
on 11/17/25
17.2000 -90.35%
on 02/13/25
-1.3300 (-44.48%)
since 12/11/24

Most Recent Stories

More News
Firefly Neuroscience Reports Third Quarter 2025 Financial Results

 – Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP...

AIFF : 1.6600 (-1.78%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Firefly Neuroscience, Inc. (NASDAQ: AIFF)

NEW YORK , Oct. 9, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Firefly Neuroscience, Inc. (NASDAQ: AIFF) on behalf of the company's shareholders.  The investigation...

AIFF : 1.6600 (-1.78%)
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...

AIFF : 1.6600 (-1.78%)
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform

– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – –...

AIFF : 1.6600 (-1.78%)
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain’s functional architecture...

AIFF : 1.6600 (-1.78%)
Firefly Neuroscience to be Added to the Russell Microcap® Index

AIFF : 1.6600 (-1.78%)
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

AIFF : 1.6600 (-1.78%)
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

AIFF : 1.6600 (-1.78%)
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementiaCalgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix...

AIFF : 1.6600 (-1.78%)
HMTXF : 0.0636 (+0.95%)
HEM.VN : 0.095 (+5.56%)
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

AIFF : 1.6600 (-1.78%)

Business Summary

Firefly Neuroscience Inc. is an AI company developing neuroscientific solutions which improve outcomes for patients with mental illnesses and neurological disorders. Firefly Neuroscience Inc., formerly known as WaveDancer Inc., is based in TORONTO.

See More

Key Turning Points

3rd Resistance Point 1.7433
2nd Resistance Point 1.7267
1st Resistance Point 1.6933
Last Price 1.6600
1st Support Level 1.6433
2nd Support Level 1.6267
3rd Support Level 1.5933

See More

52-Week High 17.2000
Fibonacci 61.8% 11.1835
Fibonacci 50% 9.3250
Fibonacci 38.2% 7.4665
Last Price 1.6600
52-Week Low 1.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar